
Opinion|Videos|April 4, 2025
Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
Experts discuss how bispecifics might be incorporated earlier in the lines of treatment for certain cancers, the steps that can be taken to improve access to bispecific therapies in underserved or rural community settings, and how partnerships among academic centers, manufacturers, and community practices can help accelerate the adoption of bispecific antibodies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How might bispecifics be incorporated earlier in the lines of treatment for certain cancers?
- What steps can be taken to improve access to bispecific therapies in underserved or rural community settings?
- How can partnerships between academic centers, manufacturers, and community practices help accelerate the adoption of bispecific antibodies?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS
2
House Panel Advances Bills to Expand Veterans’ Health Care Access
3
House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden
4
The Oncology Care Model: A Decade of Transformation
5





